Exalenz Biosciences said today it inked a collaborative deal with the Acute Liver Failure Study Group to support a study of the BreathID methacetin breath test’s ability to predict outcomes in patients with acute liver failure. The trial is slated to enroll 200 ALF patients over 2 years across 12 sites in the U.S. to test […]